Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer

A. E. C. A. B. Willemsen*, L. M. Knapen, Y. M. de Beer, R. J. M. Bruggemann, S. Croes, C. M. L. van Herpen, N. P. van Erp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)465-471
Number of pages7
JournalEuropean Journal of Clinical Pharmacology
Volume74
Issue number4
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • Cancer
  • Everolimus
  • Dried blood spot
  • Pharmacokinetics
  • Therapeutic drug monitoring
  • Method agreement
  • TANDEM MASS-SPECTROMETRY
  • RENAL-CELL CARCINOMA
  • NEUROENDOCRINE TUMORS
  • CYCLOSPORINE-A
  • PHASE-I
  • HEMATOCRIT
  • PHARMACOKINETICS
  • PERFORMANCE
  • TACROLIMUS
  • EXPOSURE
  • Predictive Value of Tests
  • Antineoplastic Agents/administration & dosage
  • Dried Blood Spot Testing
  • Humans
  • Middle Aged
  • Male
  • Tandem Mass Spectrometry
  • Drug Dosage Calculations
  • Chromatography, Liquid
  • Adult
  • Female
  • Reproducibility of Results
  • Drug Monitoring/methods
  • Aged
  • Everolimus/administration & dosage
  • Neoplasms/blood

Cite this